NZ600800A - Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same - Google Patents

Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Info

Publication number
NZ600800A
NZ600800A NZ600800A NZ60080010A NZ600800A NZ 600800 A NZ600800 A NZ 600800A NZ 600800 A NZ600800 A NZ 600800A NZ 60080010 A NZ60080010 A NZ 60080010A NZ 600800 A NZ600800 A NZ 600800A
Authority
NZ
New Zealand
Prior art keywords
pyrrolidine
methods
dione
preparing
same
Prior art date
Application number
NZ600800A
Other languages
English (en)
Inventor
Christopher A Lee
John C Kane
David P Reed
Jian-Xie Chen
Martin P Redmon
Neil R Barnes
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Priority to NZ628087A priority Critical patent/NZ628087A/en
Publication of NZ600800A publication Critical patent/NZ600800A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ600800A 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same NZ600800A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ628087A NZ628087A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (1)

Publication Number Publication Date
NZ600800A true NZ600800A (en) 2014-10-31

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ628087A NZ628087A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
NZ600800A NZ600800A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ628087A NZ628087A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR20160121602A (OSRAM)
CN (2) CN104910159A (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ628087A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TW201643163A (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
MX2014000253A (es) 2011-07-07 2014-10-17 Arqule Inc Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
CN104379144A (zh) 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
PT3665176T (pt) * 2017-08-11 2024-03-13 Actuate Therapeutics Inc Formas sólidas de 3-(5-fluorobenzofurano-3-il)-4-(5-metil-5h[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL307471A (en) * 2021-04-07 2023-12-01 Ur 1 Therapeutics Inc URAT1 inhibitor, pharmaceutical preparations and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
JP2008512496A (ja) * 2004-09-10 2008-04-24 ワイス １，３，４，９−テトラヒドロピラノ［３，４−ｂ］インドール誘導体の大規模実施可能な合成方法
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
US8513292B2 (en) * 2007-06-22 2013-08-20 Arqule, Inc. Compositions and methods for the treatment of cancer
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法

Also Published As

Publication number Publication date
MX2012007259A (es) 2015-05-15
NZ628087A (en) 2016-02-26
US8552192B2 (en) 2013-10-08
JP2013515737A (ja) 2013-05-09
US20110160242A1 (en) 2011-06-30
KR20160121602A (ko) 2016-10-19
US20160024076A1 (en) 2016-01-28
CN104910159A (zh) 2015-09-16
PH12014500310A1 (en) 2015-09-28
EP3081567A3 (en) 2016-11-16
EP2515904A2 (en) 2012-10-31
RU2556205C2 (ru) 2015-07-10
EP2515904A4 (en) 2013-07-03
PH12012501293A1 (en) 2013-01-07
CO6561823A2 (es) 2012-11-15
EP3081567A2 (en) 2016-10-19
WO2011079142A3 (en) 2011-11-24
TWI557125B (zh) 2016-11-11
SG181927A1 (en) 2012-07-30
AU2010336533B9 (en) 2015-10-08
BR112012015656A2 (pt) 2016-05-10
CA2785503A1 (en) 2011-06-30
TW201542546A (zh) 2015-11-16
US20140031551A1 (en) 2014-01-30
TW201643163A (zh) 2016-12-16
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
AU2015243015B2 (en) 2017-02-02
HK1215025A1 (zh) 2016-08-12
CN102834097B (zh) 2015-06-17
AU2010336533B2 (en) 2015-09-10
KR20120113760A (ko) 2012-10-15
TWI506026B (zh) 2015-11-01
AU2015243015A1 (en) 2015-11-05
TW201141865A (en) 2011-12-01
RU2012131344A (ru) 2014-01-27
KR101669707B1 (ko) 2016-10-27
AU2010336533A1 (en) 2012-07-12
JP2016041712A (ja) 2016-03-31
CN102834097A (zh) 2012-12-19
US9499540B2 (en) 2016-11-22
WO2011079142A2 (en) 2011-06-30
MY169232A (en) 2019-03-19
US8871933B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
NZ628087A (en) Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
MX2012013274A (es) Novedosos derivados de la pirimidina.
NZ602578A (en) Polymorphic forms st-246 and methods of preparation
MX348393B (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
UA99787C2 (en) Lactams as beta secretase inhibitors
UA106887C2 (uk) Похідні спіроциклічних амідів
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2009002807A3 (en) Indolyl pyrrolidines for the treatment of cancer
WO2008033935A3 (en) Vinorelbine derivatives
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
WO2011029775A8 (en) [1,2,4]triazolo [1,5-c]pyrimidine derivatives as hsp90 modulators
MX2010003056A (es) Polimorfos de valomaciclovir.
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
HK1207313A1 (en) Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
MY148385A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 DEC 2017 BY CULLENS

Effective date: 20150401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2022 BY THOMSON REUTERS

Effective date: 20211102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2023 BY THOMSON REUTERS

Effective date: 20221102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2024 BY THOMSON REUTERS

Effective date: 20231101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2025 BY THOMSON REUTERS

Effective date: 20241102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2026 BY THOMSON REUTERS

Effective date: 20251103